* abnormal liver function (alt, ast), chronic kidney disease or dialysis (crcl\< 30 ml/min), immunocompromised patients taking medication upon screening, subjects on warfarin or dicumarol therapy and those with comorbid condition like hypertension, hypotension, cardiovascular disease, diabetes mellitus, asthma, copd, seizures, coagulation disorder and malignancy. * patients will be also excluded if they had a known allergy to ivermectin and/or nitazoxanide, and those with contraindication towards the study medication. * pregnant women or women who are breastfeeding will be also excluded.

* abnormal liver function (alt, ast), chronic kidney disease or dialysis (crcl\< 30 ml/min), immunocompromised patients taking medication upon screening, subjects on warfarin or dicumarol therapy and those with comorbid condition like hypertension, hypotension, cardiovascular disease, diabetes mellitus, asthma, copd, seizures, coagulation disorder and malignancy. * patients will be also excluded if they had a known allergy to ivermectin and/or nitazoxanide, and those with contraindication towards the study medication. * pregnant women or women who are breastfeeding will be also excluded.

- abnormal liver function (alt, ast), chronic kidney disease or dialysis (crcl< 30 ml/min), immunocompromised patients taking medication upon screening, subjects on warfarin or dicumarol therapy and those with comorbid condition like hypertension, hypotension, cardiovascular disease, diabetes mellitus, asthma, copd, seizures, coagulation disorder and malignancy. - patients will be also excluded if they had a known allergy to ivermectin and/or nitazoxanide, and those with contraindication towards the study medication. - pregnant women or women who are breastfeeding will be also excluded.

- abnormal liver function (alt, ast), chronic kidney disease or dialysis (crcl< 30 ml/min), immunocompromised patients taking medication upon screening, subjects on warfarin or dicumarol therapy and those with comorbid condition like hypertension, hypotension, cardiovascular disease, diabetes mellitus, asthma, copd, seizures, coagulation disorder and malignancy. - patients will be also excluded if they had a known allergy to ivermectin and/or nitazoxanide, and those with contraindication towards the study medication. - pregnant women or women who are breastfeeding will be also excluded.